1. Home
  2. HAFC vs OMER Comparison

HAFC vs OMER Comparison

Compare HAFC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$27.23

Market Cap

758.9M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.69

Market Cap

894.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFC
OMER
Founded
1982
1994
Country
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
758.9M
894.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HAFC
OMER
Price
$27.23
$11.69
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$31.33
$32.50
AVG Volume (30 Days)
315.2K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.65
N/A
Revenue Next Year
$7.28
N/A
P/E Ratio
$10.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.25
$2.95
52 Week High
$30.20
$17.65

Technical Indicators

Market Signals
Indicator
HAFC
OMER
Relative Strength Index (RSI) 46.49 49.14
Support Level $26.36 $11.00
Resistance Level $28.43 $12.45
Average True Range (ATR) 0.84 0.57
MACD -0.04 0.02
Stochastic Oscillator 54.04 60.53

Price Performance

Historical Comparison
HAFC
OMER

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: